1. Home
  2. EXR vs ARGX Comparison

EXR vs ARGX Comparison

Compare EXR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXR
  • ARGX
  • Stock Information
  • Founded
  • EXR 1977
  • ARGX 2008
  • Country
  • EXR United States
  • ARGX Netherlands
  • Employees
  • EXR N/A
  • ARGX N/A
  • Industry
  • EXR Real Estate Investment Trusts
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EXR Real Estate
  • ARGX Health Care
  • Exchange
  • EXR Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • EXR 32.4B
  • ARGX 35.3B
  • IPO Year
  • EXR 2004
  • ARGX 2017
  • Fundamental
  • Price
  • EXR $151.14
  • ARGX $573.26
  • Analyst Decision
  • EXR Buy
  • ARGX Strong Buy
  • Analyst Count
  • EXR 14
  • ARGX 20
  • Target Price
  • EXR $160.86
  • ARGX $698.22
  • AVG Volume (30 Days)
  • EXR 871.8K
  • ARGX 493.8K
  • Earning Date
  • EXR 04-29-2025
  • ARGX 05-08-2025
  • Dividend Yield
  • EXR 4.29%
  • ARGX N/A
  • EPS Growth
  • EXR N/A
  • ARGX N/A
  • EPS
  • EXR 4.26
  • ARGX 15.94
  • Revenue
  • EXR $3,363,286,000.00
  • ARGX $2,643,062,000.00
  • Revenue This Year
  • EXR N/A
  • ARGX $61.64
  • Revenue Next Year
  • EXR $3.55
  • ARGX $32.00
  • P/E Ratio
  • EXR $35.49
  • ARGX $32.97
  • Revenue Growth
  • EXR 15.33
  • ARGX 82.13
  • 52 Week Low
  • EXR $121.03
  • ARGX $359.37
  • 52 Week High
  • EXR $184.87
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • EXR 58.77
  • ARGX 45.96
  • Support Level
  • EXR $142.81
  • ARGX $570.00
  • Resistance Level
  • EXR $153.37
  • ARGX $584.90
  • Average True Range (ATR)
  • EXR 3.05
  • ARGX 14.55
  • MACD
  • EXR 0.06
  • ARGX 0.82
  • Stochastic Oscillator
  • EXR 78.88
  • ARGX 66.03

About EXR Extra Space Storage Inc

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 4,000 self-storage properties in 42 states, with over 300 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: